EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSXMAG00000011090
Gene Symbol: DHCR24
3 Cross references
208 Possible Orthologues:

26s Proteasome Non-Atpase Regulatory Subunit 11b

Ensembl ID : ENSXMAG00000017949
Gene Symbol: LOC102217984
3 Cross references
220 Possible Orthologues:

26s Proteasome Non-Atpase Regulatory Subunit 4

Ensembl ID : ENSXMAG00000015234
Gene Symbol: LOC102222487
4 Cross references
226 Possible Orthologues:

26s Proteasome Non-Atpase Regulatory Subunit 4-Like

Ensembl ID : ENSXMAG00000007039
Gene Symbol: LOC102226523
3 Cross references
220 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSXMAG00000006482
Gene Symbol: HMGCR
3 Cross references
195 Possible Orthologues:

3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase

Ensembl ID : ENSXMAG00000018982
Gene Symbol: LOC102229336
3 Cross references
205 Possible Orthologues:

3-Oxo-5-Alpha-Steroid 4-Dehydrogenase 2-Like

Ensembl ID : ENSXMAG00000009822
Gene Symbol: LOC102228249
3 Cross references
208 Possible Orthologues:

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSXMAG00000018875
Gene Symbol: PDPK1
3 Cross references
221 Possible Orthologues:

4-Hydroxyphenylpyruvate Dioxygenase-Like

Ensembl ID : ENSXMAG00000015216
Gene Symbol: LOC102232563
3 Cross references
204 Possible Orthologues:

40s Ribosomal Protein S19

Ensembl ID : ENSXMAG00000024881
Gene Symbol: LOC102225777
3 Cross references
308 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSXMAG00000007577
Gene Symbol: NT5E
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSXMAG00000019710
Gene Symbol: HTR1B
4 Cross references
182 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).